Advertisement
CRSP vs NKTX
Which Stock Would AI Choose? CRISPR Therapeutics (CRSP) vs. Nkarta (NKTX) Stock Comparison
Key Takeaways
- CRSP is a commercial-stage gene-editing company with an approved therapy (Casgevy) and accelerating revenue, while NKTX is a pre-revenue, clinical-stage developer of "off-the-shelf" natural killer (NK) cell therapies.
- CRSP carries a roughly $5 billion market capitalization with comparatively moderate volatility; NKTX trades near the single-digit range with a sub-$300 million market cap and substantially higher volatility.
- Both names are driven by binary clinical and regulatory catalysts, but CRSP's diversified pipeline and commercial validation give it a more stable relative market positioning.
- Tickeron AI Verdict: CRSP is the favored ticker in this comparison, based on stronger trend consistency, commercial-stage stability, and broader institutional support.
- For more detail, explore CRSP Major News and CRSP Today's Price Move, as well as NKTX Major News and NKTX Today's Price Move.
- Interested in automated strategies? Explore Trending AI Robots to see which AI trading bots are best suited to current market conditions.
Introduction
Biotechnology stocks can produce outsized returns, but they also carry elevated risk tied to clinical trials, regulatory decisions, and commercial launches. This stock comparison examines two companies pursuing cell-based and genetic medicines: CRSP (CRISPR Therapeutics AG), a leader in CRISPR gene editing, and NKTX (Nkarta, Inc.), a developer of engineered natural killer (NK) cell therapies. Both operate in the high-growth oncology and autoimmune treatment space, yet they sit at very different stages of maturity. This analysis is relevant for growth-oriented investors and traders assessing relative performance, market positioning, and risk across two names with distinct profiles.
CRSP Overview and Recent Performance
CRSP, or CRISPR Therapeutics AG, develops gene-based medicines using its CRISPR/Cas9 platform. Its most significant achievement to date is Casgevy, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), developed in partnership with Vertex Pharmaceuticals. Casgevy was one of the first CRISPR-based therapies approved in the United States, giving CRSP a rare commercial-stage position in the gene-editing field.
In recent weeks, CRSP has traded in a range around the mid-to-high $40s to low $50s, with a market capitalization near $5 billion. Sentiment has been shaped by accelerating Casgevy sales—reported at roughly $76 million in the second quarter of 2026, up sharply year over year—alongside a U.S. label expansion to younger patients. The company also maintains a diversified pipeline, including CTX310 (targeting lipid-related cardiovascular risk), CTX611 (an investigational anticoagulant), and "off-the-shelf" CAR-T candidates such as CTX112 and CTX131. Recent analyst activity has leaned positive, with several firms raising price targets on Casgevy demand and pipeline catalysts, though CRSP remains unprofitable and carries clinical-execution risk.
NKTX Overview and Recent Performance
NKTX, or Nkarta, Inc., is a clinical-stage biopharmaceutical company developing allogeneic, "off-the-shelf" engineered natural killer (NK) cell therapies—treatments that can be manufactured in advance and administered without the delays of patient-specific cell harvesting. Its lead programs are NKX019, a CAR NK (chimeric antigen receptor natural killer) candidate targeting CD19 for autoimmune disease, and NKX101, a CAR NK candidate for certain blood cancers.
In recent market activity, NKTX has shown significant volatility, trading in the low single digits with a market capitalization well below $300 million. The stock has experienced sharp percentage swings in both directions, consistent with a pre-revenue, catalyst-driven small-cap profile. Analysts covering the name have generally maintained Buy or Strong Buy ratings with price targets well above current levels, reflecting optimism about NKX019's autoimmune opportunity and recent progress, including regulatory protocol adjustments. However, the company remains pre-revenue, continues to post quarterly net losses, and faces substantial dilution and clinical-risk considerations typical of early-stage biotech.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of AI trading bots drawn from a marketplace of hundreds of automated systems. These bots collectively trade thousands of different tickers and operate across varied timeframes—ranging from 5-minute and 15-minute intraday intervals to 60-minute and end-of-day horizons—with distinct trading styles, strategies, and published performance statistics. Because not every bot suits every market environment, only those considered best aligned with current conditions earn a place in the trending section. Each bot discloses its closed-trade history, allowing users to review metrics such as trade frequency, win rates, and risk parameters before following a strategy. For traders seeking a systematic, data-driven complement to their research, reviewing the Trending AI Robots is a practical next step.
Head-to-Head Comparison
These two companies differ most sharply in stage of development and risk profile. CRSP is commercial-stage: it has an approved product generating meaningful revenue, a diversified pipeline spanning gene editing and cell therapy, a cash-rich balance sheet, and a market capitalization orders of magnitude larger than its peer. Its growth story centers on expanding Casgevy's patient base and advancing later-stage pipeline candidates toward approval.
NKTX, by contrast, is pre-revenue. Its value proposition rests entirely on clinical validation of its NK cell platform, particularly NKX019 in autoimmune disease. This creates a higher ceiling of potential upside per analyst price targets but also far greater downside risk, as reflected in its volatility and single-digit share price. NKTX has fewer commercial de-risking events to point to and remains dependent on capital raises to fund ongoing trials.
In terms of market sentiment, both stocks have attracted analyst support, but CRSP's is broader and anchored to realized revenue, whereas NKTX's is more speculative and tied to trial outcomes. Sector exposure is similar—both target oncology and autoimmune diseases—but their business models differ: gene editing versus cell therapy. For risk-tolerant traders, NKTX offers higher beta and catalyst-driven moves; for investors prioritizing stability and demonstrated execution, CRSP presents a more established profile.
Tickeron AI Verdict
Based on observable factors—trend consistency, commercial-stage stability, revenue growth, liquidity, and relative market positioning—Tickeron's AI would currently favor CRSP over NKTX in this stock comparison. CRSP's combination of an approved, revenue-generating therapy, a deep pipeline, and a more stable trading profile suggests stronger consistency of trend and a lower probability of the kind of outsized drawdowns common to early-stage biotech. NKTX may offer greater upside potential per its analyst targets, but that potential is accompanied by meaningfully higher risk and volatility. The AI's preference is probabilistic rather than definitive, grounded in the relative stability and validated commercial footing that CRSP currently demonstrates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and NKTX is a Hold.
CRSP in +5.42% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.498). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CRSP | NKTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 97 | |
PRICE GROWTH RATING 1..100 | 69 | 84 | |
P/E GROWTH RATING 1..100 | 54 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (24) in the Biotechnology industry is in the same range as NKTX (37) in the null industry. This means that CRSP’s stock grew similarly to NKTX’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NKTX (100) in the null industry. This means that CRSP’s stock grew similarly to NKTX’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NKTX (97) in the null industry. This means that CRSP’s stock grew similarly to NKTX’s over the last 12 months.
CRSP's Price Growth Rating (69) in the Biotechnology industry is in the same range as NKTX (84) in the null industry. This means that CRSP’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (14) in the null industry is somewhat better than the same rating for CRSP (54) in the Biotechnology industry. This means that NKTX’s stock grew somewhat faster than CRSP’s over the last 12 months.
| CRSP | NKTX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 83% | N/A |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 87% |
| Advances ODDS (%) | 14 days ago 82% | 8 days ago 84% |
| Declines ODDS (%) | 2 days ago 81% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 1 green, 4 red.
- NKTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 3 TA indicator(s) are bullish while NKTX’s TA Score has 5 bullish TA indicator(s).
- CRSP’s TA Score: 3 bullish, 6 bearish.
- NKTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
CRSP (@Biotechnology) experienced а -9.68% price change this week, while NKTX (@Biotechnology) price change was -11.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CRSP is expected to report earnings on Feb 16, 2027.
NKTX is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -15.09% | ||
| CRSP - NKTX | 49% Loosely correlated | -9.77% | ||
| EDIT - NKTX | 47% Loosely correlated | -8.91% | ||
| PROK - NKTX | 45% Loosely correlated | -3.48% | ||
| VIR - NKTX | 45% Loosely correlated | -3.63% | ||
| RNAC - NKTX | 45% Loosely correlated | -1.85% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RESM | 23.55 | -0.08 | -0.34% |
| Columbia Research Enhanced Small Cap ETF (RESM) | |||
| BASG | 27.70 | -0.16 | -0.56% |
| Brown Advisory Sustainable Growth ETF (BASG) | |||
| SPRX | 33.32 | -0.28 | -0.83% |
| Spear Alpha ETF (SPRX) | |||
| EMSF | 34.14 | -0.30 | -0.86% |
| Matthews Emerging Markets Sustainable Future Active ETF (EMSF) | |||
| BPRE | 12.20 | -0.28 | -2.24% |
| Bluerock Private Real Estate Fund | |||